• Zephlex

  Led · Equity · Jan 2024

  Zephlex Bilgi Teknolojileri operates the Sentiment Algo brand, delivering AI‑supported, behavior‑based algorithms for data analysis, trading robots, fund management strategies, research and education. Its customers include leading brokerage firms and portfolio management companies, and it serves retail users via web and mobile applications. The company reports serving directly or indirectly 25% of brokerages with active trading volume on the exchange. Zephlex is based in Yıldız Teknik Üniversitesi Teknopark and benefits from TÜBİTAK and KOSGEB R&D incentives and projects. It completed the UptoRaise accelerator prior to the announced investment. With the new funding the company is targeting expansion into overseas and crypto markets and is accelerating work to establish a foreign subsidiary.

• OmniGuide

  Participated · Equity · May 2008

  OmniGuide Surgical develops and manufactures the BeamPath® Laser System, a flexible fiber-enabled CO2 laser platform for minimally invasive surgery. The company designs and manufactures its system in Cambridge, Massachusetts using proprietary technology invented at MIT. The BeamPath system has been used in nearly 100,000 surgical procedures, primarily in Gynecology and ENT. OmniGuide positions CO2 laser energy as causing less tissue damage versus other advanced energy products, which it says can improve surgeon experience and patient outcomes. The company distributes the BeamPath Laser System in the U.S. through a direct sales force. OmniGuide recently closed a $15 million equity financing to support commercialization and product launches into the ENT market and further growth in Gynecology. OmniGuide is a Cambridge, Massachusetts-based medical device company specializing in advanced energy surgical products for the operating room. Its core product is the BeamPath® flexible laser system, which has been used in over 40,000 adult and pediatric surgical procedures across gynecology, ENT and neurosurgery. The company’s fiber products are based on proprietary technology invented at MIT and originally published in Science and Nature. OmniGuide distributes in the U.S. through a direct sales force and in Europe through distribution partners. Led by President and CEO Scott Flora, the company intends to use the proceeds of the recent financing to accelerate commercialization of its advanced energy surgical products. The company closed a $35M financing with an affiliate of OrbiMed Advisors. OmniGuide produces BeamPath, a flexible optical fiber used to guide CO2 laser beams in surgery. The company said it will use the new funding to expand its laser surgery business. BeamPath has been used in more than 3,000 surgeries, including procedures for head and neck cancers, airway clearing, and hearing restoration. More than 200 hospitals in the U.S. and Europe use the system. OmniGuide reported $2 million in revenue last year and CEO Yoel Fink told VentureWire he expects the company to be profitable in 2009. The company has about 80 employees and originally licensed the technology from MIT. OmniGuide is based in Cambridge, Mass.

No current team members are available.